anti ki67 rabbit monoclonal antibody  (Boster Bio)

Journal: Molecular Therapy. Nucleic Acids

Article Title: Metabolic beneficial effects of targeting a long non-coding RNA, lnc-megacluster, in obesity

doi: 10.1016/j.omtn.2025.102792

Figure Lengend Snippet: High-fat diet (HFD)-induced obesity and impaired insulin sensitivity are attenuated in lncMGC KO mice (A) Representative images of wild type (WT) and lncMGC KO control (Con) and HFD-fed male and female mice after 20 weeks on the HFD. (B–D) Biweekly body weight gain, (C) endpoint body weight, (D) gWAT weight, (E) total fat mass, (n = 7–8 mice/group), and (F) adipocyte size (5/group), in male and female mice. (G–I) plasma insulin levels, (H) HOMA-IR, and (I) area under the curve (AUC) for GTT, in male and female mice. (J–L) IHC staining of F4/80 (macrophage inflammation marker) and CD31 (endothelial cell marker) in gWAT sections from WT and lncMGC KO male and female mice. Scale bars, 50 μm. Quantitative analysis of (K) F4/80 ( n = 5/group) and (L) CD31 ( n = 5/group) in male and female mice. (M) Gene expression of lncMGC (n = 4-7, lncMGC was not detected by qPCR in 4 samples in lncMGC KO HFD mice ), Chop , Vegfb , and Pparg in isolated stromal vascular fraction (SVF) from gWAT in male and female mice (n = 7–8/group). Statistical analyses were performed by two-way ANOVA with post-hoc Tukey test for multiple comparisons. Student’s t tests for comparisons between two groups. XY graphs show the mean (SD). The bar and whisker plot displays the distribution of the data. The whiskers extend from the minimum to the maximum values. Individual data points are overlaid as dots. Statistically significant p values are indicated in the bar graphs.

Article Snippet: For IHC, the following primary antibodies were used: anti-UCP-1 (1:100, ab10983, Abcam); anti-FIS-1 Rabbit polyclonal antibody (1:100, 10956-1-AP, Proteintech, USA); anti-SDHB (1:200, 10620-1-A, Proteintech, USA); ani-YBX1(1:500, LS- B12352 , LSBio, USA); and rabbit monoclonal antibody anti-CD31(1:50, 77699, cell signaling) and anti-F4/80 (1:100, 70076, cell signaling) and anti-CHOP (1:50, 15204-1-AP, Proteintech, USA).

Techniques: Control, Clinical Proteomics, Immunohistochemistry, Marker, Gene Expression, Isolation, Whisker Assay

Journal: Molecular Therapy. Nucleic Acids

Article Title: Metabolic beneficial effects of targeting a long non-coding RNA, lnc-megacluster, in obesity

doi: 10.1016/j.omtn.2025.102792

Figure Lengend Snippet: lncMGC-GapmeR treatment reduces the rate of weight gain and improves insulin sensitivity in HFD-fed mice (A) Representative images show GapmeR accumulation in gWAT in HFD/NC and HFD/Gap mice by in situ hybridization with a fluorescent antisense LNA-modified probe. (B) Gene expression of mlncMGC (n = 4–5/group) in HFD/NC and HFD/Gap mice. (C–H)Weekly body weight gain, (D) endpoint body weight, (E) total body fat, (F) plasma insulin levels, (G) Homeostatic model assessment HOMA-IR, and (H) area under the curve (AUC) for glucose tolerance test (GTT) in male and female mice. (I–L) IHC staining of F4/80 (macrophage marker) and CD31 (endothelial cell marker) in gWAT in male and female mice. Scale bars, 50 μm; 40× magnification. Quantitative analysis of (J) adipocyte size, (K) F4/80, and (L) CD31. n = 5/group. (M) Gene expression of Vegfb (angiogenesis marker) Chop (ER stress marker) Pparg and Cebpb (adipogenesis markers) in gWAT in male and female mice. Control chow-diet (Con), high-fat diet (HFD), negative control (NC) GapmeR (HFD/NC), GapmeR targeting lncMGC (HFD/Gap). Statistical analyses were performed by two-way ANOVA with post-hoc Tukey test for multiple comparisons. XY graphs show the mean (SD). The bar and whisker plot displays the distribution of the data. The whiskers extend from the minimum to the maximum values. Individual data points are overlaid as dots. Statistically significant p -values are indicated in the bar graphs.

Article Snippet: For IHC, the following primary antibodies were used: anti-UCP-1 (1:100, ab10983, Abcam); anti-FIS-1 Rabbit polyclonal antibody (1:100, 10956-1-AP, Proteintech, USA); anti-SDHB (1:200, 10620-1-A, Proteintech, USA); ani-YBX1(1:500, LS- B12352 , LSBio, USA); and rabbit monoclonal antibody anti-CD31(1:50, 77699, cell signaling) and anti-F4/80 (1:100, 70076, cell signaling) and anti-CHOP (1:50, 15204-1-AP, Proteintech, USA).

Techniques: In Situ Hybridization, Modification, Gene Expression, Clinical Proteomics, Immunohistochemistry, Marker, Control, Negative Control, Whisker Assay

Journal: Molecular Therapy. Nucleic Acids

Article Title: Metabolic beneficial effects of targeting a long non-coding RNA, lnc-megacluster, in obesity

doi: 10.1016/j.omtn.2025.102792

Figure Lengend Snippet: hlncMGC-GapmeR treatment reduces the rate of weight gain and improves key functional markers in gWAT and BAT of partially humanized lncMGC HFD-fed female mice (A) Expression of lncMGC in white adipose tissue (WAT) samples obtained from human lean and overweight/obese donors. (B) Weekly and (C) endpoint body weight, (D) total body fat in partially humanized female mice fed HFD for 10 weeks. (E) Representative images show GapmeR accumulation (red signals) in gWAT in partially humanized lncMGC HFD/GapmeR (hHFD/Gap) female mice by in situ hybridization. (F) Expression of hlncMGC in gWAT in negative control (NC) GapmeR (hHFD/NC) and hHFD/Gap humanized mice (n = 5–7/group) and (G) IHC staining of CD31 in gWAT sections. (H) Quantitative analysis of adipocyte size and CD31. n = 5/group. (I) H&E staining shows a significant reduction of lipid droplets and whitening of BAT in hHFD/Gap mice. (I) IHC staining and (J) quantitative analysis of UCP-1, FIS1, SDHB, and YBX1 in BAT. n = 5/group. Scale bars, 50 μm; 40× magnification. Control chow-diet (hCon), high-fat diet (hHFD). Statistical analyses were performed by two-way ANOVA with post-hoc Tukey test for multiple comparisons. XY graph shows mean SD. The whiskers extend from the minimum to the maximum values. Individual data points are overlaid as dots. Statistically significant p values are indicated in the bar graphs.

Article Snippet: For IHC, the following primary antibodies were used: anti-UCP-1 (1:100, ab10983, Abcam); anti-FIS-1 Rabbit polyclonal antibody (1:100, 10956-1-AP, Proteintech, USA); anti-SDHB (1:200, 10620-1-A, Proteintech, USA); ani-YBX1(1:500, LS- B12352 , LSBio, USA); and rabbit monoclonal antibody anti-CD31(1:50, 77699, cell signaling) and anti-F4/80 (1:100, 70076, cell signaling) and anti-CHOP (1:50, 15204-1-AP, Proteintech, USA).

Techniques: Functional Assay, Expressing, In Situ Hybridization, Negative Control, Immunohistochemistry, Staining, Control

Journal: Journal of Inflammation Research

Article Title: Association of Increased Nasal Fluids-Serum Concordance of Protein Profile with Prognosis in Nasal Polyps

doi: 10.2147/JIR.S567454

Figure Lengend Snippet: Expression validation of LIFR in CRSwNP. ( A ) Transcriptional levels of biomarkers (LIFR, LIF, IL-5, IL-13) in PR versus non-PR groups. ELISA quantification of LIFR concentrations in both ( B ) serum and ( C ) NF of PR patients compared to non-PR and control groups. ( D ) Representative images of H&E and LIFR immunohistochemical staining (Magnification ×400). ( E ) Quantification of LIFR protein expression intensity (n=6/group). ( F and G ) scRNA-seq analysis of CRSwNP tissues showing LIFR expression patterns across cell populations (left: cell type clusters; right: LIFR expression). ( H ) Immunofluorescence of LIFR (red) co-localization with vascular endothelial cells (CD31+, green) and nuclear staining (DAPI, blue) at ×400 magnifications (n=6/group). * P < 0.05, ** P < 0.01, **** P < 0.0001.

Article Snippet: For immunofluorescence, endothelial cells in nasal mucosa were marked using an anti-CD31 antibody (Bioss #bsm-10825M).

Techniques: Expressing, Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Control, Immunohistochemical staining, Staining, Immunofluorescence

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: Ferroptosis and vascular arrest are present in the rat model of BPD induced by hyperoxia. A Comparison of body size and lung volume of rats after euthanasia; B Weight plot of rats in CON and BPD groups; C HE staining of rat lung tissue, scale bar: 50 μm; D Determination of mRNA contents of PTGS2, SLC7A11 and GPX4 in rat lung tissues, GAPDH was used as an internal control; E Quantitative analysis of radial alveolar count in rat lung tissues by HE staining; F - G . Protein expression and gray value quantitative analysis of PTGS2, SLC7A11 and GPX4 in lung tissue of rats, GAPDH was used as a whole protein internal control; The levels of LPO, MDA, SOD and GSH in serum of ( H - K ). L Determination of VEGFA and CD31 mRNA content in rat lung tissue, GAPDH was used as internal control; Protein expression and gray value quantification of VEGFA and CD31 in lung tissues of ( M - N ). GAPDH was used as a whole protein internal control. N = 6, p < 0.05 for statistically significant (* p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Comparison, Staining, Control, Expressing

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: The intervention of SP alleviates vascular retardation in BPD rats. A body weight of rats; B - C HE staining and RAC number in rat lung tissue, scale bar: 50 μm; D - E detection of VEGFA and CD31 mRNA in lung tissue of rats, GAPDH was used as internal control; F - H . protein detection of VEGFA and CD31 in lung tissue of rats, GAPDH was used as the whole protein internal control, and the gray value was quantified. The results shown were observed in at least three independent experiments. N = 6, p < 0.05 for statistically significant (* p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001, ns: no difference)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Staining, Control

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: SP alleviated vascular development arrest in HUVEC cell model. A The concentration of SP intervention cells was screened, and the cell survival rate was measured by CCK8; B - C mRNA detection of VEGFA and CD31 in HUVEC cells, GAPDH was used as internal control; D CD31 immunofluorescence detection; E protein detection of VEGFA and CD31 in cells, GAPDH was used as internal control; F fluorescence detection of VEGFA; G Quantitative calculation of gray value of Western blot experiment; H Quantification of immunofluorescence of HUVEC cells. Scale bar =50 μm. N =6, p <0.05 was considered statistically significant (* p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001, ns: no difference)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Concentration Assay, Control, Immunofluorescence, Fluorescence, Western Blot

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: Effect of SLC7A11 knockdown on SP intervention. A - C SLC7A11 siRNA knockdown efficiency was detected by RT-qPCR and Western blot; D - E PTGS2, CD31 and VEGFA protein detection and gray value quantification of HUVECs, GAPDH was used as an internal control; F - H , J Fluorescence plots and quantification of LPO and ROS of HUVECs, scale scale =100 μm, This fluorescent probe can emit red fluorescence under normal circumstances, and the fluorescence will change from red to green as lipid peroxidation occurs. The formation of lipid peroxides can be detected with high sensitivity through the fluorescence intensities of red and green.; I GSH measurement of HUVEC. Two-sided unpaired t test was used for comparison between the two groups. N =6, p <0.05 was considered statistically significant (* p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001, ns: no difference)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Knockdown, Quantitative RT-PCR, Western Blot, Control, Fluorescence, Comparison

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: Effect of GPX4 knockdown on SP intervention. A - C GPX4 siRNA knockdown efficiency was detected by RT-PCR and western blot; D - E PTGS2, CD31 and VEGFA protein detection and gray value quantification of HUVECs, GAPDH was used as an internal control; F - H , J Fluorescence plots and quantification of LPO and ROS of HUVEC, scale scale =100 μm, This fluorescent probe can emit red fluorescence under normal circumstances, and the fluorescence will change from red to green as lipid peroxidation occurs. The formation of lipid peroxides can be detected with high sensitivity through the fluorescence intensities of red and green.; I GSH measurement of HUVECs. Two-sided unpaired t test was used for comparison between the two groups. N =6, p <0.05 was considered statistically significant (* p <0.05, ** p <0.01, *** p <0.001, ns: no difference)

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Knockdown, Reverse Transcription Polymerase Chain Reaction, Western Blot, Control, Fluorescence, Comparison

Journal: Respiratory Research

Article Title: Sodium propionate alleviates bronchopulmonary dysplasia by inhibiting ferroptosis through the SLC7A11/GPX4 pathway in pulmonary endothelial cells

doi: 10.1186/s12931-026-03535-3

Figure Lengend Snippet: A proposed mechanistic model illustrating how SP alleviates BPD. In HUVECs, hyperoxia exposure suppresses the SLC7A11/GPX4 antioxidant axis, leading to increased lipid peroxidation (LPO) and reactive oxygen species (ROS), thereby triggering ferroptosis. Concurrently, the expression of pro-angiogenic factors (VEGFA, CD31) is downregulated, resulting in impaired vascular development and alveolar simplification—the hallmark pathological features of BPD. SP treatment counteracts hyperoxia-induced damage by upregulating the SLC7A11/GPX4 pathway. The activation of this axis inhibits ferroptosis (reducing LPO and ROS) and restores the expression of VEGFA and CD31, thereby promoting angiogenesis and preserving alveolar structure. This model summarizes the core finding: SP exerts protective effects against BPD by modulating ferroptosis and vascular development through the SLC7A11/GPX4 signaling axis

Article Snippet: The GAPDH and CD31 antibodies were procured from Proteintech (Cat No.60004-1-Ig, Cat No.11265-1-AP, Wuhan, China), while the PTGS2, SLC7A11, GPX4, and VEGFA antibodies were acquired from MedChemExpress (HY- P80091 , HY- P80935 , HY- P80450 , HY- P80929 , MCE, USA).

Techniques: Expressing, Activation Assay, Preserving